Health
NICE okays regular NHS funding for Novartis’ breast cancer drug Kisqali – – pharmaphorum
NICE has recommended moving Novartis’ Kisqali (ribociclib) from interim funding arrangements to regular NHS reimbursement for previously treated breast cancer patients….
NICE has recommended moving Novartis Kisqali (ribociclib) from interim funding arrangements to regular NHS reimbursement for certain previously treated breast cancer patients.
In the final draft guidance, NICE recommended Kiskali be taken out of the Cancer Drugs Fund, which has been providing interim reimbursement since 2019 until further trial data emerged addressing uncertainties about overall survival and cost-effectiveness.
These data are now available from the phase 3 MONALEESA-3, a randomised…
-
Noosa News22 hours agoThe Laundry Lady secures $1M to fuel international expansion
-
Noosa News19 hours agoTruffle growers say rare delicacy is worth its $3,500 per kilo expense
-
Noosa News12 hours agoWhere, when and why? Everything you need to know about Sunday’s pro-Palestine protest march in Brisbane
-
Noosa News19 hours agoHomicide investigation underway after woman found dead in north Brisbane